Walmart has finalized a settlement agreement with the U.S. Department of Justice (DOJ) to resolve a federal lawsuit concerning the company's pharmacy practices. The retail giant will pay $50 million to settle claims that its pharmacies filled hundreds of thousands of prescriptions for controlled substances that did not meet legal requirements. The lawsuit, which was originally filed in 2020, alleged that Walmart failed to adequately monitor and report suspicious orders of opioids, thereby contributing to the broader national opioid crisis.

Under the terms of the settlement, Walmart is required to address the systemic failures identified by federal investigators. The DOJ contended that the company’s internal systems for flagging potentially illegal or excessive prescriptions were insufficient, allowing a high volume of opioids to reach the public without proper oversight. By agreeing to the settlement, Walmart avoids a protracted court battle, though the company has faced significant scrutiny regarding its role as a major pharmacy provider during the height of the opioid epidemic. This settlement is part of a larger series of legal actions taken by the federal government against various entities involved in the distribution and dispensing of prescription painkillers. While the $50 million figure represents a significant financial penalty, it concludes the specific litigation initiated by the DOJ four years ago, bringing a formal end to the government's claims of regulatory negligence in this specific case.